Global Peptide Therapeutics Market 2016-2020
SKU ID :TNV-10291819 | Published Date: 04-Mar-2016 | No. of pages: 81Description
TOC
PART 01: Executive summary
• Highlights
PART 02: Scope of the report
• Market overview
• Top-vendor offerings
PART 03: Market research methodology
• Research methodology
• Economic indicators
PART 04: Introduction
• Key market highlights
PART 05: Overview of peptides
• Peptide synthesis
• Optimization of peptides
• Stabilization of peptides
• PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 07: Market segmentation based on route of administration
• Parenteral
• Oral
• Pulmonary
• Mucosal
PART 08: Market segmentation by drug class
• Somatostatins
• Vasopressin
• Calcitonins
• Luteinizing hormone (LH)-releasing hormone (LHRH)
• Glucagon and analogs
• Insulins
• Other
PART 09: Market segmentation by synthesis technology
• Liquid-phase peptide synthesis
• Solid-phase peptide synthesis
• Hybrid peptide synthesis
PART 10: Geographical segmentation
• Global peptide therapeutics market segmentation by geography 2015-2020
• Peptide therapeutics market in Americas
• Peptide therapeutics market in EMEA
• Peptide therapeutics market in APAC
PART 11: Market drivers
• Increase in patient population
• Advances in peptide synthesis technology
• Promising pipeline
• Unmet medical needs
• Increase in healthcare spending
PART 12: Impact of drivers
PART 13: Market challenges
• High cost of therapy
• Adverse side effects
• Stringent regulatory compliances
• Intense market competition
PART 14: Impact of drivers and challenges
PART 15: Market trends
• Growing popularity
• Shifting focus toward untapped markets
• Contract manufacturing
• Increase in public awareness
PART 16: Vendor landscape
• Competitive scenario
• Eli Lilly
• Novo Nordisk
• Sanofi
• Takeda Pharmaceutical
• Teva Pharmaceuticals
• Other prominent vendors
PART 17: Appendix
• List of abbreviations
PART 18: Explore Technavio
List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: SWOT analysis: Peptide therapeutics
Exhibit 03: Steps involved in peptide synthesis
Exhibit 04: Optimization of peptide synthesis
Exhibit 05: Methods used to stabilize peptides
Exhibit 06: Global peptide therapeutics market 2015-2020 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Global peptide therapeutics market segmentation based on route of administration
Exhibit 09: Global peptide therapeutics market segmentation by route of administration 2015
Exhibit 10: Global peptide therapeutics market segmentation by drug class
Exhibit 11: Global peptide therapeutics market segmentation by synthesis technology
Exhibit 12: Global peptide therapeutics market segmentation by geography 2015
Exhibit 13: Peptide therapeutics market revenue by geography 2015-2020 ($ billions)
Exhibit 14: Peptide therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 15: Peptide therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 16: Peptide therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 17: Global peptide therapeutics market: YoY growth and revenue based on geography 2015-2020
Exhibit 18: Impact of drivers
Exhibit 19: Impact of drivers and challenges
Exhibit 20: El Lilly: YoY growth rate and revenue of Humalog 2012-2014 ($ billions)
Exhibit 21: Eli Lilly: YoY growth rate and revenue of Cialis 2012-2014 ($ billions)
Exhibit 22: Eli Lilly: YoY growth rate and revenue of Cymbalta 2012-2014 ($ billions)
Exhibit 23: Eli Lilly: YoY growth rate and revenue of Humulin 2012-2014 ($ billions)
Exhibit 24: Eli Lilly: YoY growth rate and revenue of Forteo 2012-2014 ($ billions)
Exhibit 25: Eli Lilly: Key takeaways
Exhibit 26: Novo Nordisk: YoY growth rate and revenue of NovoLog/NovoRapid 2012-2014 ($ billions)
Exhibit 27: Novo Nordisk: Geographical split of revenues of NovoLog 2014
Exhibit 28: Novo Nordisk: YoY growth rate and revenue of NovoMix/NovoLog mix 2012-2014 ($ billions)
Exhibit 29: Novo Nordisk: Geographical split of revenues of NovoMix 2014
Exhibit 30: Novo Nordisk: YoY growth rate and revenue of Norditropin 2012-2014 ($ billions)
Exhibit 31: Novo Nordisk: Geographical split of revenues of Norditropin 2014
Exhibit 32: Novo Nordisk: YoY growth rate and revenue of Prandin 2012-2014 ($ millions)
Exhibit 33: Novo Nordisk: Geographical split of revenues of Prandin 2014
Exhibit 34: Novo Nordisk: Key takeaways
Exhibit 35: Sanofi: YoY growth rates and revenues of Lantus 2012-2014 ($ billions)
Exhibit 36: Sanofi: YoY growth rate and revenue of Amaryl 2012-2014 ($ millions)
Exhibit 37: Sanofi: YoY growth rate and revenue of Apidra 2012-2014 ($ millions)
Exhibit 38: Sanofi: YoY growth rate and of Insuman 2012-2014 ($ millions)
Exhibit 39: Sanofi: YoY revenue of Lyxumia 2013-2014 ($ millions)
Exhibit 40: Sanofi: Key takeaways
Exhibit 41: Takeda Pharmaceutical: YoY revenue of Velcade 2013-2014 ($ billions)
Exhibit 42: Takeda Pharmaceutical: YoY revenue of Leuprorelin 2013-2014 ($ billions)
Exhibit 43: Takeda Pharmaceutical: YoY revenue of Nesina 2013-2014 ($ millions)
Exhibit 44: Takeda Pharmaceutical: YoY revenue of TachoSil 2013-2014 ($ millions)
Exhibit 45: Takeda Pharmaceutical: Key takeaways
Exhibit 46: Teva Pharmaceuticals: YoY growth rate and revenue of Copaxone 2012-2014 ($ billions)
Exhibit 47: Teva Pharmaceuticals: Key takeaways
Tables & Figures
Companies
Eli Lilly, Novo Nordisk, Sanofi, Takeda Pharmaceutical, Teva Pharmaceuticals, AbbVie, Advanced Accelerator Applications, Akashi Therapeutics, Amgen, Anthera Pharmaceuticals, AstraZeneca, Bachem, Bristol-Myers Squibb, Cardiorentis, Corden Pharma International, Debiopharm, Derma Sciences, GlaxoSmithKline, Hanmi Pharmaceutical, Insmed, Ipsen, Johnson & Johnson, Lonza, Mallinckrodt, MolMed, Merck, Novartis, Nymox Pharmaceutical, Par Pharmaceuticals, PeptiDream, Polypeptide Group, Radius Health, Repligen, Roche, SciClone, Shire, The Medicines Company, Transition Therapeutics, X-Gen Pharmaceuticals, Zealand Pharma, Zydus Cadila.
- PRICE
-
$2500$4000